Beta
Empagliflozin
medicationSGLT2 inhibitor (brand name: Jardiance) for type 2 diabetes. Shows cardiovascular and kidney protection benefits. Used in some longevity protocols.
Reported Benefits
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
Not specified
This randomized trial evaluates empagliflozin 10 mg daily for 6 months in people without diabetes but with cardiovascular risk factors, assessing changes in cardiac structure via MRI, biomarkers like NT-proBNP, blood pressure, and hematocrit.
Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Nervous Activity in Patients With Type 2 Diabetes Mellitus: A Randomized Clinical Trial
Not specified in available details
In this study of participants without healthy status but assessed for sympathetic activity, empagliflozin 25 mg daily for 12 weeks lowered cardiac filling pressures without increasing sympathetic nervous activity; it was well-tolerated with fewer adverse events than placebo.
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
Not specified
This randomized trial evaluates empagliflozin 10 mg daily for 6 months in people without diabetes but with cardiovascular risk factors, assessing changes in cardiac structure via MRI, biomarkers like NT-proBNP, blood pressure, and hematocrit.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Research (2 studies)
Community updates
No updates yet for this supplement.
Be the first to share your experience!